{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:39:49Z","timestamp":1790840389061,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015805","name":"Tianjin Industrial and Information Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01595","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T14:17:07Z","timestamp":1596809827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes"],"prefix":"10.3389","volume":"10","author":[{"given":"Fanqiao","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes.","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/ajh.24102","article-title":"Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.","volume":"90","author":"Garcia-Manero","year":"2015","journal-title":"Am J Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/ajh.23513","article-title":"Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.","volume":"88","author":"Jabbour","year":"2013","journal-title":"Am J Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cca.2018.01.029","article-title":"Discriminating myelodysplastic syndrome and other myeloid malignancies from non-clonal disorders by multiparametric analysis of automated cell data.","volume":"480","author":"Kim","year":"2018","journal-title":"Clin Chim Acta."},{"key":"B5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ejh.13111","article-title":"Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.","volume":"101","author":"Kattamis","year":"2018","journal-title":"Eur J Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jhm.2049","article-title":"Myelodysplastic syndromes: what do hospitalists need to know?","volume":"8","author":"Zeidan","year":"2013","journal-title":"J Hosp Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.6004\/jnccn.2011.0006","article-title":"Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010.","volume":"9","author":"Sekeres","year":"2011","journal-title":"J Natl Compr Canc Netw."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0192-x","article-title":"Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation.","volume":"9","author":"Ishiyama","year":"2019","journal-title":"Blood Cancer J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12185-015-1747-7","article-title":"Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.","volume":"101","author":"Patel","year":"2015","journal-title":"Int J Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/cncr.30532","article-title":"Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?","volume":"123","author":"Stahl","year":"2017","journal-title":"Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00262-019-02343-7","article-title":"Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.","volume":"68","author":"Krijgsman","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1466769","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.","volume":"7","author":"Hung","year":"2018","journal-title":"Oncoimmunology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function.","volume":"188","author":"Lozano","year":"2012","journal-title":"J Immunol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2019-9-2","article-title":"Combination checkpoint inhibitors for treatment of nonsmall-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1\/PD-L1 therapies.","volume":"2020","author":"Puri","year":"","journal-title":"Drugs Context."},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00262-019-02299-8","article-title":"The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.","volume":"68","author":"Agdashian","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle.","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060877","article-title":"DNAM-1 and the TIGIT\/PVRIG\/TACTILE Axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy.","volume":"11","author":"Sanchez-Correa","year":"2019","journal-title":"Cancers."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0486-z","article-title":"Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.","volume":"10","author":"Zhu","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.","volume":"134","author":"Armand","year":"2019","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","article-title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.","volume":"2","author":"Sarhan","year":"2018","journal-title":"Blood Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma.","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset.","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/bloodadvances.2019000242","article-title":"Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.","volume":"3","author":"Zhao","year":"2019","journal-title":"Blood Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology.","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw."},{"key":"B27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3324\/haematol.2014.118679","article-title":"Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.","volume":"100","author":"Hejazi","year":"2015","journal-title":"Haematologica."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-Cell Immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients.","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/JLB.MA0119-021R","article-title":"A skewed distribution and increased PD-1+Vbeta+CD4+\/CD8+ T cells in patients with acute myeloid leukemia.","volume":"106","author":"Huang","year":"2019","journal-title":"J Leukoc Biol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106198","article-title":"Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).","volume":"80","author":"Sun","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hon.2375","article-title":"PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.","volume":"35","author":"Four","year":"2017","journal-title":"Hematol Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","article-title":"Targeting PVR (CD155) and its receptors in anti-tumor therapy.","volume":"16","author":"Kucan Brlic","year":"2019","journal-title":"Cell Mol Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint.","volume":"200","author":"Harjunpaa","year":"2019","journal-title":"Clin Exp Immunol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat7061","article-title":"Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype.","volume":"3","author":"Wang","year":"2018","journal-title":"Sci Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma.","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1590\/1414-431X20144051","article-title":"Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.","volume":"48","author":"Xiong","year":"2015","journal-title":"Braz J Med Biol Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients.","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T14:25:41Z","timestamp":1597069541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":39,"alternative-id":["10.3389\/fonc.2020.01595"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01595","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"article-number":"1595"}}